Optimind Pharma Corp. (CSE:OMND)
0.0050
0.00 (0.00%)
At close: Sep 11, 2025
Optimind Pharma Income Statement
Financials in millions CAD. Fiscal year is March - February.
Millions CAD. Fiscal year is Mar - Feb.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
| 0.09 | 0.12 | 0.12 | 0.12 | 0.17 | 0.1 | |
Revenue Growth | -26.11% | 2.47% | -3.73% | -27.72% | 70.64% | - |
Cost of Revenue | 0.04 | 0.05 | 0.05 | 0.06 | 0.12 | 0.04 |
Gross Profit | 0.05 | 0.08 | 0.07 | 0.06 | 0.05 | 0.06 |
Selling, General & Admin | 0.12 | 0.12 | 0.27 | 0.51 | 0.92 | 0.44 |
Research & Development | - | - | - | 0.12 | - | - |
Amortization of Goodwill & Intangibles | - | - | - | - | 0.01 | 0.01 |
Operating Expenses | 0.12 | 0.12 | 0.27 | 0.81 | 0.96 | 0.47 |
Operating Income | -0.06 | -0.04 | -0.2 | -0.75 | -0.91 | -0.4 |
Interest Expense | - | - | - | -0.09 | -0.07 | -0.02 |
Other Non Operating Income (Expenses) | -0.02 | -0.03 | -0.01 | -0.21 | -0.03 | - |
EBT Excluding Unusual Items | -0.09 | -0.07 | -0.22 | -1.05 | -1.01 | -0.42 |
Impairment of Goodwill | - | - | - | - | -0.86 | - |
Gain (Loss) on Sale of Investments | -0.05 | -0.05 | - | - | -0.31 | - |
Asset Writedown | - | - | - | -0.37 | -0.65 | - |
Other Unusual Items | - | - | - | 0.02 | -0.26 | - |
Pretax Income | -0.14 | -0.12 | -0.22 | -1.41 | -3.09 | -0.42 |
Income Tax Expense | - | - | - | -0.01 | -0.01 | -0.14 |
Net Income | -0.14 | -0.12 | -0.22 | -1.4 | -3.08 | -0.28 |
Net Income to Common | -0.14 | -0.12 | -0.22 | -1.4 | -3.08 | -0.28 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 103 | 104 | 111 | 100 | 82 | 44 |
Shares Outstanding (Diluted) | 103 | 104 | 111 | 100 | 82 | 44 |
Shares Change | -4.25% | -7.14% | 12.00% | 21.38% | 88.09% | - |
EPS (Basic) | -0.00 | -0.00 | -0.00 | -0.01 | -0.04 | -0.01 |
EPS (Diluted) | -0.00 | -0.00 | -0.00 | -0.01 | -0.04 | -0.01 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Gross Margin | 59.53% | 62.33% | 58.27% | 47.63% | 30.49% | 63.89% |
Operating Margin | -70.90% | -35.27% | -170.38% | -612.59% | -533.41% | -405.39% |
Profit Margin | -149.48% | -97.23% | -182.32% | -1136.63% | -1809.57% | -278.57% |
EBITDA | - | - | - | -0.74 | -0.89 | -0.39 |
D&A For EBITDA | - | - | - | 0.01 | 0.01 | 0.01 |
EBIT | -0.06 | -0.04 | -0.2 | -0.75 | -0.91 | -0.4 |
EBIT Margin | -70.90% | -35.27% | -170.38% | - | - | - |